4.930EUR+1.44%Mkt Cap: 124.27M EURP/E: —Last update: 2026-05-14
OSE Immunotherapeutics SA, a clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally. Its products include Tedopi that is in Ph…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)—
P/E (Forward)-4.90
PEG—
P/B3.56
P/S70.77
EV/EBITDA-3.61
EV/Revenue59.63
EPS (TTM)-1.69
EPS (Forward)-1.11
Cash Flow & Leverage
FCF Yield-13.44%
FCF Margin-937.63%
Operating CF48.44M EUR
CapEx (TTM)77.00K EUR
Net Debt/EBITDA0.44
Net Debt-12.98M EUR
Technical
SMA 503.562 (+38.4%)
SMA 2004.995 (-1.3%)
Beta0.79
S&P 52W Chg24.23%
Avg Vol (30d)296.22K
Avg Vol (10d)338.04K
Technical Indicators
RSI (14)71.4
MACD0.3102
MACD Signal0.1657
MACD Hist.+0.1445
BB Upper4.923 EUR
BB Middle3.769 EUR
BB Lower2.615 EUR
BB Width61.25%
ATR (14)0.4603 EUR
Vol Ratio (20d)2.74x
52W Range
2.87243% of range7.700
52W High7.700 EUR
52W Low2.872 EUR
Profitability
Gross Margin100.00%
EBITDA Margin0.00%
Profit Margin53.59%
Oper. Margin-2272.16%
ROE58.68%
ROA30.21%
Revenue Growth-0.80%
Earnings Growth—
Balance Sheet
Debt/Equity0.72
Current Ratio1.54
Quick Ratio1.19
Book Value/Sh1.524 EUR
Cash/Share2.687 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Ownership
Shares Out.23.27M
Float15.90M
Insiders27.45%
Institutions2.74%
Analyst Consensus
Rating1.0 (Strong Buy)
Target (Mean)14.07 EUR
Target Range8.200 EUR – 21.00 EUR
# Analysts3
Company
Market Cap124.27M EUR
Enterprise Value106.25M EUR
Revenue (TTM)1.78M EUR
Gross Profit1.78M EUR
Net Income (TTM)37.45M EUR
Revenue/Share0.0810 EUR
Fiscal Year EndDec 2025
MR QuarterDec 2024
Employees64
Last Price4.930 EUR
CountryFR
SectorHealthcare
IndustryBiotechnology
ISINFR0012127173